The continued data lag is most likely a way that adverse reactions that should be counted as such can be rejected- Last report showed no increase in adverse reactions for a specific time period for the first time ever and this week looks to follow the same pattern.-
With the numbers for May 14th looking virtually unchanged. That’s implausible, 2 weeks in a row, considering the numbers of jabs given.
Reported weekly adverse events are linked to 2,581,148 jabs. (Jabs from recent report to present) I don’t put any real faith in the incomplete data now or the "updated" data, should that really occur? Nevertheless I’ll follow what is provided.
*25,387,552 Total doses administered
* 6,864 Total adverse event following immunization reports
(0.027% of all doses administered)
*5,473 Total adverse event following immunization reports that were non-serious
(0.022% of all doses administered)
*1,391 Total adverse event following immunization reports that were serious
(0.005% of all doses administered)
*192 New adverse event following immunization reports since last update
(75 new non-serious and 117 new serious)
We see the serious adverse events outnumber the non serious.
*Up to and including June 4, 2021, a total of 104 deaths were reported after the administration of a vaccine.
Weekly or otherwise has always been unknown to me- So 104? Or a cumulative total of 606 plus 104 equals 710 deaths. In the US if we check the VAERS - the cumulative death total is 5888
Making the 710 the more likelier number for deaths with vaccine in Canada- Knowing that adverse affects are grossly under reported both here and in the US.
* Cases of thrombosis with thrombocytopenia syndrome following vaccination with AstraZeneca/COVISHIELD COVID-19 vaccine continue to be monitored.
This is also an issue with Moderna and Pfizer...Worse with AZ yes, but, the cases of thrombosis with thrombocytopenia syndrome following vaccination occur with all vaccines.
“Up to and including June 4, 2021, there were 50 cases of TTS in Canada with reports submitted to PHAC or to Health Canada. Of the TTS cases:
46 cases received COVISHIELD/AstraZeneca vaccines, three received a Pfizer vaccine, and one received a Moderna vaccine.”
We should be aware that many of these cases were initially missed.. So what is the true number? Unknown. (previously covered)
* “PHAC and Health Canada are also monitoring international reports (World Health Organization, United States Centers for Disease Control and Prevention, European Medicines Agency, Israel) of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines.”
Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining around the heart.
Up to and including June 4, 2021, there were 35 cases of myocarditis/pericarditis with reports submitted to PHAC or Health Canada. Of the myocarditis/pericarditis cases:
25 cases received Pfizer-BioNTech COVID-19 vaccine, 6 cases received Moderna vaccine, 3 cases received COVISHIELD/AstraZeneca vaccines, and the vaccine name of one was not specified
Symptom onset ranged from 5 hours to 94 days
19 were females [median age 51 years (age range 20 to 78 years old)] and 16 were males [median age 40 years (age range 29 to 70 years old)].
22 reports following the first vaccine dose, 11 report following the second vaccine dose; dose for two was not specified
My last post covered the outsized cases of heart inflammation among the young in the US.
More than half of the cases reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) after people had received their second dose of either the Pfizer/BioNTech or Moderna vaccines were in people between the ages of 12 and 24, the CDC said.Oh and about those J& J vaccines- Canada will not be using them.
Those age groups accounted for less than 9% of doses administered.
9 percent of the doses administered and more then 50% of the adverse reaction reports for heart inflammation- Do you see a problem with that? I certainly do!
"We clearly have an imbalance there," Dr. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, said in a presentation download to an advisory committee to the U.S. Food and Drug Administration meeting on Thursday.
Health Canada said it has completed its quality review of the shipment and has decided not to distribute them to provinces to "protect the health and safety of Canadians" amid concerns over the Baltimore facility part of the vaccine was produced at.
The J&J vaccine doses were previously being held for review after arriving in Canada upon learning that a drug substance used in the vaccine was produced at the Emergent BioSolutions' Baltimore facility.
Even though.. Canada previously okayed and used 1.5 million Astra Zeneca Injections that were manufactured in the same facility
AstraZeneca's shot is no longer being made at the Baltimore facility, and Health Canada previously said that the 1.5 million doses of AstraZeneca it had imported from this facility were safe and met quality specifications.Oh, really?
Recall that biologics (these genetic therapy vaccines) are prone to contamination?
“biologics are complex mixtures that are not easily identified or characterized. Biological products, including those manufactured by biotechnology, tend to be heat sensitive and susceptible to microbial contamination”
Week after week